Pharvaris N.V. — 2022 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone Q4 filing; the text does not provide clear Q4-only financial results. Financial statements are prepared under IFRS in euros. Pharvaris is a clinical-stage biopharmaceutical company developing oral deucrictibant for hereditary angioedema (HAE); it has no approved products or product revenue.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | €57.4 million | €35.8 million |
| General and administrative expense | €29.3 million | €18.3 million |
| Total operating expenses | €86.7 million | €54.1 million |
| Net loss | €76.3 million | €42.7 million |
| Basic and diluted loss per share | €2.27 | €1.40 |
| Net cash used in operating activities | €67.2 million | €44.6 million |
| Cash and cash equivalents at year-end | €161.8 million | €209.4 million |
- Net finance income was €11.1 million, mostly unrealized foreign-exchange gains from translating U.S.-dollar cash balances. This materially reduced the reported loss before tax; it is not operating income.
- At December 31, 2022, total assets were €167.7 million, equity €149.3 million and total liabilities €18.5 million. The filing reports no borrowings; lease liabilities were €0.44 million.
- Cash declined by €58.6 million during 2022, despite €11.1 million of favorable exchange-rate effects. Financing provided €8.7 million, principally from ATM share sales; 588,100 shares generated net proceeds of approximately €9.2 million.
- Management said available cash was expected to fund the operating plan and liabilities for at least 12 months from issuance of the financial statements on April 5, 2023. The company expects continued operating cash outflows and remains dependent on future financing.
- Contractual service commitments totaled €28.0 million, including €21.8 million due within one year. Up to €10.5 million of additional AnalytiCon milestone payments remain contingent; low-to-mid single-digit royalties would apply to licensed-product sales.
Material changes versus 2021
- Net loss increased 79% to €76.3 million, as total operating expenses rose 60% to €86.7 million.
- R&D expense rose 60%, mainly as programs moved from Phase 1 into global Phase 2 studies and open-label extensions, with higher clinical and manufacturing costs.
- G&A expense rose 60%, reflecting organizational growth, share-based compensation and commercial preparation.
- Operating cash use increased 51% to €67.2 million. Year-end cash fell 23%, following substantial IPO proceeds in 2021 and continued development spending.
- Share-based compensation expense increased to €11.3 million from €8.2 million. The company ended 2022 with 33,816,459 ordinary shares outstanding.
Clinical outlook, risks and unusual items
- FDA clinical holds: In August 2022, the FDA placed U.S. deucrictibant trials under clinical hold after reviewing nonclinical findings. The FDA requested an additional long-term rodent toxicology study and an updated Investigator’s Brochure. The 26-week study had begun; Pharvaris expected to submit results by the end of 2023. The FDA partially lifted the on-demand hold to allow two remaining U.S. RAPIDe-1 participants to complete treatment. Full lifting of the holds was not assured.
- Clinical progress: Pharvaris reported positive topline Phase 2 RAPIDe-1 results in December 2022: all three PHVS416 dose levels met the primary symptom-relief endpoint and key secondary endpoints, with less rescue-medication use versus placebo. The company reported no treatment-related serious adverse events or adverse-event discontinuations. These are company-reported topline results, not evidence of regulatory approval.
- Prophylaxis: CHAPTER-1, a Phase 2 study, was ongoing outside the U.S.; data were expected in the second half of 2023. Phase 1 data for extended-release PHVS719 supported potential once-daily dosing. A registration-directed on-demand trial and pivotal prophylaxis work were planned, subject to regulatory discussions and clinical progress.
- Management expects R&D spending to increase in 2023. There is no revenue guidance or quantified earnings outlook; commercial revenue depends on successful development, regulatory approval and commercialization.
- Key risks include the unresolved clinical holds, uncertain efficacy and safety in later-stage trials, clinical and manufacturing delays, reliance on third-party CROs/CDMOs, financing needs, competition and pricing/reimbursement uncertainty. COVID-19 and the Russia-Ukraine conflict could disrupt trials and supply chains.
- Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end because of material weaknesses in documented risk assessment and controls, staffing, review procedures, segregation of duties and IT controls. Remediation actions included hiring, formalizing controls and implementing a new accounting system. The auditor issued an unqualified opinion on the financial statements but did not attest to internal-control effectiveness.
- The company reported no material litigation affecting its financial position and no contingent liabilities at year-end. Its 2022 financial statements were audited under IFRS; the audit report was dated April 5, 2023.
Most important facts for investors to verify
- Current FDA status and outcome of the 26-week toxicology study, including whether U.S. holds have been fully lifted.
- Complete RAPIDe-1 results and whether they support the planned confirmatory trial; verify CHAPTER-1 results and the PHVS719 dose and safety profile.
- Cash runway against the rising operating burn, committed service costs and potential milestone obligations; assess whether additional financing or dilution may be needed.
- Progress in remediating internal-control weaknesses and whether controls operate effectively over a sustained period.
- Whether clinical benefits and safety are confirmed in larger trials; comparisons with icatibant are not head-to-head clinical comparisons.